,;where e is base of natural logarithm, e = 2.72, Z is calculated by formula Z = (-5.1 + (0.08) * x + (0.066) * y), x is content of IL-17 in blood serum in pg/ml, y – content of IL-6 in blood serum in pg/ml, and risk of developing adverse cardiovascular events is considered to be high while value K ≥ 0.13, and low – while K 0.13.;EFFECT: use of the method enables higher accuracy of assessing the risk of unfavorable outcomes for 1 year after the percutaneous coronary intervention with stenting in the patients with stable coronary artery disease, which in turn will allow optimizing the therapeutic approach in these patients.;1 cl, 1 dwg, 3 tbl, 2 ex"/> METHOD FOR ASSESSING THE RISK OF DEVELOPING ADVERSE OUTCOMES WITHIN THE FIRST YEAR FOLLOWING THE PERCUTANEOUS CORONARY INTERVENTION WITH STENTING IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE
首页> 外国专利> METHOD FOR ASSESSING THE RISK OF DEVELOPING ADVERSE OUTCOMES WITHIN THE FIRST YEAR FOLLOWING THE PERCUTANEOUS CORONARY INTERVENTION WITH STENTING IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE

METHOD FOR ASSESSING THE RISK OF DEVELOPING ADVERSE OUTCOMES WITHIN THE FIRST YEAR FOLLOWING THE PERCUTANEOUS CORONARY INTERVENTION WITH STENTING IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE

机译:冠状动脉介入治疗合并缺血性心脏病的患者在冠状动脉介入治疗后的第一年评估不良结果风险的方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to cardiology, and can be used to predict the risk of adverse outcomes in patients with stable ischemic heart disease within 1 year after a percutaneous coronary intervention with stenting. Method comprises determining initial levels of interleukin-17 (IL-17) and interleukin-6 (IL-6) in blood serum by enzyme-linked immunosorbent assay, and then calculating risk of unfavorable outcomes by formula; ,;where e is base of natural logarithm, e = 2.72, Z is calculated by formula Z = (-5.1 + (0.08) * x + (0.066) * y), x is content of IL-17 in blood serum in pg/ml, y – content of IL-6 in blood serum in pg/ml, and risk of developing adverse cardiovascular events is considered to be high while value K ≥ 0.13, and low – while K 0.13.;EFFECT: use of the method enables higher accuracy of assessing the risk of unfavorable outcomes for 1 year after the percutaneous coronary intervention with stenting in the patients with stable coronary artery disease, which in turn will allow optimizing the therapeutic approach in these patients.;1 cl, 1 dwg, 3 tbl, 2 ex
机译:技术领域本发明涉及医学,即心脏病学,并且可以用于预测在经支架的经皮冠状动脉介入治疗后1年之内稳定的缺血性心脏病患者不良后果的风险。该方法包括通过酶联免疫吸附测定法测定血清中白细胞介素17(IL-17)和白细胞介素6(IL-6)的初始水平,然后通过公式计算不良结果的风险; ,其中e是自然对数的底数,e = 2.72,Z由公式计算Z =(-5.1 +(0.08)* x +(0.066)* y),x是血清中IL-17的含量,以pg / ml为单位,y –血清中IL-6的含量,以pg / ml为单位,以及值K≥0.13时,发生心血管不良事件的风险较高,而K值<0.13时则较低;;效果:该方法的使用可提高经皮冠状动脉介入治疗1年后不良结局风险的评估准确性。在稳定的冠状动脉疾病患者中采用支架置入术,这反过来又可以优化这些患者的治疗方法。1cl,1 dwg,3 tbl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号